The latest price target for Gilead Sciences (NASDAQ:GILD) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $70.00 expecting GILD to fall to within 12 months (a possible -16.57% downside). 34 analyst firms have reported ratings in the last year.

The latest analyst rating for Gilead Sciences (NASDAQ:GILD) was provided by Cantor Fitzgerald, and Gilead Sciences reiterated their neutral rating.

The last upgrade for Gilead Sciences Inc happened on July 8, 2024 when Raymond James raised their price target to $93. Raymond James previously had a market perform for Gilead Sciences Inc.

The last downgrade for Gilead Sciences Inc happened on February 22, 2024 when Truist Securities changed their price target from $91 to $82 for Gilead Sciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a reiterated with a price target of $70.00 to $70.00. The current price Gilead Sciences (GILD) is trading at is $83.90, which is out of the analyst’s predicted range.